SAFC showcases HPAPI handling capabilities

By Gareth Macdonald

30-Oct-2008 Last updated on 28-Sep-2021 at 11:50 GMT

SAFC's Mike Harris sets out the firm's role in the expanding high-potency active pharmaceutical ingredient (HPAPI) industry.

Drugmakers within EC's REACH, says SAFC

08-Sep-2008

Despite a decade-long build up, drugmakers are yet to wake up to the “no data, no market” mantra of the EC’s REACH legislation, according to SAFC’s marketing director Amanda Halford.

Headlines

Gilead recruits Terray in AI-driven drug discovery pact

Palatin reports positive phase 2b results in type 2 diabetic nephropathy

AbbVie acquires Roche immune drug spinout in $200 million deal

Products

By Univar Solutions USA

Solution for challenging antibodies – Planova™ S20N

By Asahi Kasei Medical Co., Ltd.

Accurate determination of resin substitution in solid phase peptide synthesis

By Almac Group

Promotional features

Streamlining early phase drug development with continuous flow technologies

Paid for and in partnership with Lonza Small Molecules

Achieving data integrity: Best practices for secure and reliable data management

Paid for and content provided by METTLER TOLEDO

AI transforms route scouting for faster drug synthesis

Paid for and in partnership with Lonza Small Molecules

Outsourcing-Pharma

Advertise with us
Apply to reuse our contentOpens in new window
Press Releases - Guidelines
About us
Contact us
Why Register?

Resources

Report a technical problem
Whitelist our newsletters
Help Centre
RSS Feed
Podcast
Archives

SAFC showcases HPAPI handling capabilities

SAFC's Mike Harris sets out the firm's role in the expanding high-potency active pharmaceutical ingredient (HPAPI) industry.

Related Topics

Drugmakers within EC's REACH, says SAFC